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Streszczenie
Wstęp W pierwotnym nadciśnieniu tętniczym zaburzenia
gospodarki węglowodanowej (ZW) często współistnieją
z zaburzeniami funkcji śródbłonka naczyń (ED).
Materiał i metody Celem pracy była ocena wpływu antago-
nisty receptora AT1 — losartanu 50 mg/dz. — oraz inhibi-
tora ACE — trandolaprilu 2 mg/dz. — na zaburzenia go-
spodarki węglowodanowej i dysfunkcję śródbłonka w pier-
wotnym, dotychczas nieleczonym nadciśnieniu tętniczym.
We krwi na czczo oceniano: glukozę, insulinę, całkowitą
homocysteinę, HbA1c, kwas moczowy, czynnik von Wille-
branda (vWF:Ag) oraz HOMA-IR, BMI, WHR u chorych
z nadciśnieniem łagodnym do umiarkowanego w porówna-
niu z grupą odpowiednią kontrolną. Ocena została powtó-
rzona w obu leczonych grupach po 3 miesiącach
Wyniki W obu leczonych grupach, poza obniżeniem warto-
ści ciśnienia, uzyskano także obniżenie stężenia HbA1c, co
sugeruje korzystny wpływ farmakoterapii na (ZW). Stwier-
dzono obniżenie vWF:Ag w grupie losartanu i wzrost
vWF:Ag w grupie trandolaprilu. Różny wpływ na vWF:Ag
(traktowany jako marker uszkodzenia śródbłonka) można
tłumaczyć poprzez odmienny mechanizm ingerencji bada-
nych leków na układ RAA oraz przez prawdopodobny udział
układu kinin, których aktywność jest wzmożona w trakcie
terapii inhibitorem ACE. Grupa trandolaprilu cechowała się
wyższym wskaźnikiem talia-biodra (WHR) w porównaniu
z grupą kontrolną (niż grupa losartanu), co może sugerować
występowanie poważniejszych ZW, spowodowanych zwięk-
szoną ilością tkanki tłuszczowej brzusznej. Grupa trandola-
prilu miała wyższe stężenia glukozy, HbA1c, całkowitej ho-
mocysteiny niż grupa losartanu w porównaniu z grupą kon-
trolną (przed leczeniem).
Wnioski Dane autorów sugerują, że grupa chorych z łagod-
nym do umiarkowanego nadciśnieniem tętniczym, chociaż
klinicznie podobna, może w różny sposób odpowiadać na
farmakoterapię, co może być efektem stopnia zaawansowa-
nia zaburzeń metabolicznych występujących jeszcze przed
leczeniem.
słowa kluczowe: HbA1c, pierwotne nadciśnienie tętnicze,
losartan, trandolapril, czynnik von Willebranda
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Introduction
Essential arterial hypertension (EH) is an impor-
tant cause of nephropathy and chronic renal failure
and so remains a medical and economic problem for
society. Contemporary EH treatment focuses on
many aspects, especially on making a positive impact
on metabolic disturbances and impaired endothelial
function [1]. The carbohydrate metabolism distur-
bances (CM) observed in EH patients are conducive
to endothelial dysfunction (ED), signifying an im-
balance between vasodilation and vasoconstriction.
ED is considered to be a crucial initial step in the
progression of atherosclerosis and hyperhomocystein-
aemia is believed to be a risk factor in this process [2].
ACE inhibitors occupy a prominent position in the
therapy of EH, although angiotensin II receptor 1 (AT1)
antagonists attract much attention. The role of ACE
inhibitors is to block the tissue and systemic renin-angio-
tensin-aldosterone systems. The inhibition of angio-
tensin I to II enzymatic conversion and the prevention
of bradykinin degradation result in the positive clinical
effects of ACE inhibitors. The significant importance of
the increased bradykinin tissue amount has been un-
derstood recently. This vasodilator peptide influences
the vascular endothelium, stimulating arachidonic acid
metabolism, which increases prostacyklin biosynthesis.
Another positive effect of higher bradykinin levels is the
increase in nitric oxide (NO) production [3].
On the other hand the AT1 receptor antagonists
which bind selectively to the angiotensin II AT1 recep-
tors inhibit the biological function of angiotensin II
and increase its serum concentration. In this way
more angiotensin II interacts with the second class of
its receptors, AT2, which results in elevated NO pro-
duction and vasodilatation [4]. The aim of this study,
therefore, was to compare ACE inhibitor trandolapril
and AT1 antagonist losartan monotherapy as regards
metabolism, mainly CM and ED, in previously non-
-treated mild to moderate EH patients.
Material and methods
A comparison was made between 25 non-microalbu-
minuric at baseline, non-diabetic (on the basis of fast-
ing glucose level) ambulatory patients with untreated
EH (11F/14M) staged, according to WHO, at phases I
or II and 14 controls (7F/7M) matched for age. The
EH patients were divided into two groups. Group A:
12 patients (5F/7M) were given AT1-antagonist losar-
tan in a dose of 50 mg. Group B: 13 patients (7F/6M)
were given ACE inhibitor trandolapril in a dose of 2 mg.
The drugs were given for 3 months. Before and after
the 3-month therapy the following samples were col-
lected: 24h urine for albumin excretion and N-acetyl-b-
-D-glucosaminidase (NAG), creatinine and fasting
blood for insulin, glucose, homocysteine, glycated hae-
moglobin (HbA1c) and uric acid. The study protocol
was approved by the Ethics Committee at The Ludwik
Rydygier Medical University, Bydgoszcz. Written in-
formed consent was obtained from all the patients.
NAG was measured with a colorimetric assay using
a Boehringer Mannheim reagent kit (3-cresolsulfon-
phtaleinyl-N-acetyl-b-D-glucosaminidase sodium salt
as a substrate). The results were corrected for creatinine
urine concentration. Microalbuminuria was measured
by a turbidimetric method (Dade Behring) on a Turbi-
timer analyser. Total homocysteine was measured on
an IMX analyser (Fluororescence Polarisation Immu-
noassay FPIA-Abbott Laboratories). Insulin was meas-
ured on an AxSym analyser (Microparticle Enzyme Im-
munoassay-MEIA, Abbott Laboratories). The content
of glycated haemoglobin A1c (%) was calculated on an
IMX analyser (MEIA technology, Abbott Laboratories).
Glucose levels (enzymatic test, Roche) and creatinine
levels (Jaffé method, Roche) were measured on a Hi-
tachi 912 analyser. Insulin resistance was evaluated by
the homeostasis model assessment (HOMA-IR), which
was calculated from: HOMA-IR = fasting plasma in-
sulin (µU/mL) ¥ fasting plasma glucose (mmol/l)/22.5.
Uric acid was measured on a Hitachi 912 analyser by
the BioMerieux immunoenzymatic method. The von
Willebrand Factor was measured by the immunoenzy-
matic method using anty-vWF:Ag antibodies (IgG)
from Dako, Denmark. The results were shown in per-
centages of the vWF:Ag activity in referential serum.
Arterial blood pressure was measured by the Ko-
rotkow method (phases I and V) with a standardised
mercury sphygmomanometer, the patients having
been in the sitting position for 5 minutes. MAP (mean
arterial pressure) was calculated as diastolic blood
pressure plus 1/3 pulse pressure. WHR (waist to hip
ratio) and BMI (body mass index) were calculated.
The results are expressed as a mean ± standard devia-
tion when normal distribution is found. Data without
normal distribution is presented as median and range.
The Statistica 5 program was used to perform the sta-
tistical analysis. A p < 0.05 was considered to be sta-
tistically significant. The SN abbreviation was used to
represent no significance. The significance of differ-
ences between means of measurements for two groups
was determined by Student’s test or the Cochran-Cox
test for paired data after an analysis of variances by the
Fisher test. Also the U-Mann-Whitney non-paramet-
ric test was used for unpaired data without normal
distribution. Pearson’s correlation coefficients were
performed to assess linear relationship.
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Results
Patients of group B were distinguished by higher
WHR, HbA1c, glucose and homocysteine in compari-
son with the controls, while the patients in group A did
not differ from the controls in this respect (tab. I, II).
However, it must be emphasised that when a compa-
rison between groups A and B was made (tab. III),
group B was characterised by lower vWF:Ag and high-
er fasting glucose before treatment only. The other pa-
rameters measured did not differ between groups A
and B. Tables IV and V show the effects of both losar-
tan and trandolapril therapy on the parameters calcu-
lated. In both groups MAP and HbA1c fell to the same
extent during therapy. Although losartan therapy low-
ered vWF:Ag, the trandolapril group showed the op-
posite effect on vWF:Ag. Before therapy the following
linear correlation was found exclusively in group A:
vWF:Ag vs. glucose (r = –0.63; p < 0.05) while in
group B the following were found: HbA1c vs. insulin
(r = 0.57; p < 0.05) and HbA1c vs. HOMA-IR (r = 0.61;
p < 0.05). No other linear correlation was found in
either group, either before or after therapy. There was
no significant difference in albuminuria (mg/24 h) be-
tween groups A and B (13.62 ± 6.30 vs. 16.06 ± 7.68;
pNS), between these groups and the controls (16.18 ±
± 15.13; pNS) and no significant change of albuminu-
ria was noticed in groups A and B after treatment.
Discussion
During the 3-month treatment there were no ad-
verse events in either group of patients. Hyperin-
sulinemia, elevated HOMA-IR, hyperglycaemia and
increased HbA1c may suggest the presence of insulin
resistance in the patients in the present study and this
is in agreement with others [5]. The hyperinsulinae-
mia found in EH may indirectly lower uric acid excre-
tion, which may explain the hyperuricaemia in our
patients. However the possibility cannot be excluded
that the intrarenal vessel damage found in EH may
contribute to a lowering of uric acid urine excretion.
The EPIC-Norfolk study proved that HbA1c is an in-
Table I. Characteristics of patients in group A and B before treatment comparing to controls
Tabela I. Charakterystyka pacjentów grup A i B przed leczeniem w porównaniu z grupą kontrolną
Parameter Group A vs. controls p Group B  vs. controls p Controls
Age (years)  39.50 ± 12.63 NS  44.77 ± 12.17 NS 40.07 ± 11.18
BMI   28.33 ± 4.80  < 0.05   28.54 ± 4.21  < 0.01  23.07 ± 2.43
WHR 0,91 ± 0,11 NS 0.90 ± 0.08  < 0.05 0.83 ± 0.10
MAP [mm Hg]  124 ± 8.5    < 0.01  127 ± 9.61  < 0.01   84 ± 10.5
Systolic blood pressure [mm Hg]  164 ± 14.4  < 0.01  167 ± 6.93  < 0.01  115 ± 14.3
Diastolic blood pressure [mm Hg]  104 ± 6.9  < 0.01  106 ± 6.9  < 0.01  68 ± 9.0
WHR, waist/hip ratio, MAP, mean arterial pressure, BMI, body mass index
Table II. Characteristics of patients in group A and B before treatment comparing to controls
Tabela II. Charakterystyka pacjentów grup A i B przed leczeniem w porównaniu z grupą kontrolną
Parameters Group A  vs. controls p Group B vs. controls p Controls
HbA1c (%) 6.01 (4.96–6.85) NS 6.09 (5.22–6.73)  < 0.05 5.66 (4.73–7.63)
Insulin [mU/mL]   13.74 ± 7.57  < 0.01   11.37 ± 5.86  < 0.01 6.87 ± 2.10
Glucose [mmol/L] 5.17 ± 0.56 NS 5.66 ± 0.41  < 0.05 5.08 ± 0.41
HOMA-IR  3.17 ± 1.71    < 0.01 2.89 ± 1.61  < 0.05 1.59 ± 0.53
Uric acid [mmol/L]  377 ± 93    < 0.01   328 ± 81  < 0.05  263 ± 71
Homocysteine [mmol/L] 8.83 ± 3.05 NS  10.49 ± 2.53  < 0.05 8.39 ± 2.55
NAG [IU/g creat] 1,89 (1.24–7.45) NS 2.68 (1.00–10.6) NS 1.29 (0.25–5.89)
vWF:Ag (%) 267 (130–490)    < 0.01 130 (39–264)  < 0.05 95 (71–120)
HOMA-IR, insulin resistance homeostasis model assessment
nadciśnienie tętnicze rok 2004, tom 8, nr 1
48 www.nt.viamedica.pl
Table IV. The characteristics of group A before [I] and after [II] Losartan therapy
Tabela IV. Charakterystyka pacjentów grupy A przed [I] i po [II] leczeniu losartanem
Parameters Group A [I] Group A [II] P
MAP [mm Hg]  124 ± 8.5  100 ± 7.1  < 0.01
HbA1c (%) 6.01 (4.96–6.85) 5.84 (4.67–6.54)  < 0.05
Insulin [mU/mL]  13.74 ± 7.57  12.66 ± 7.38 NS
Glucose [mmol/L] 5.17 ± 0.56 5.45 ± 0.84 NS
HOMA-IR 3.17 ± 1.71 3.25 ± 2.33 NS
Uric acid [mmol/L]  377 ± 93  368 ± 86 NS
Homocysteine [mmol/L] 8.83 ± 3.05 9.93 ± 2.37 NS
NAG [IU/g creat] 1.89 (1.24–7.45) 2.86 (0.75–6.71) NS
vWF:Ag (%) 267 (130–490) 145 (48–384)  < 0.02
HOMA-IR, insulin resistance homeostasis model assessment
Table V. The characteristics of group B before [I] and after [II] Trandolapril therapy
Tabela V. Charakterystyka pacjentów grupy B przed [I] i po [II] leczeniu trandolaprilem
Parameters Group B [I] Group B [II] p
MAP [mm Hg]   127 ± 9.61    97 ± 6.03  < 0.001
HbA1c (%) 6.09 (5.22–6.73) 5.68 (5.09–6,40)  < 0.05
Insulin [mU/mL]  11.37 ± 5.86  11.06 ± 6.55 NS
Glucose [mmol/L]  5.66 ± 0.41 5.43 ± 0.41 NS
HOMA-IR  2.89 ± 1.61 2.65 ± 1.52 NS
Uric acid [mmol/L]  328 ± 81  334 ± 11 NS
Homocysteine [mmol/L]  10.49 ± 2.53  10.74 ± 2.55 NS
NAG [IU/g creat] 2.68 (1.00–10.6) 2.33 (0.56–4.63) NS
vWF:Ag (%) 130 (39–264) 276 (90–547)  < 0.01
HOMA-IR, insulin resistance homeostasis model assessment
Table III. Characteristics of patients in group A and B before treatment
Tabela III. Porównanie pacjentów grup A i B przed leczeniem
Parameter Group A Group B p
Age (years) 39.50 ± 12.63 44.77 ± 12.17 NS
BMI   28.33 ± 4.80  28.54 ± 4.21 NS
WHR  0.91 ± 0.11 0.90 ± 0.08 NS
MAP [mm Hg]  124 ± 8.5  127 ± 9.61 NS
Insulin [mU/mL]   13.74 ± 7.57  11.37 ± 5.86 NS
Glucose [mmol/L] 5.17 ± 0.56 5.66 ± 0.41 < 0.05
HOMA-IR 3.17 ± 1.71 2.89 ± 1.61 NS
Uric acid [mmol/L]   377 ± 93   328 ± 81 NS
Homocysteine [mmol/L] 8.83 ± 3.05  10.49 ± 2.53 NS
NAG [IU/g creat] 1.89 (1.24–7.45) 2.68 (1.00–10.6) NS
vWF:Ag (%) 267 (130–490) 130 (39–264) < 0.01
WHR, waist/hip ratio, MAP, mean arterial pressure, BMI, body mass index
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dependent cardiovascular disease risk factor and a pre-
dictor of cardiovascular as well as all other causes of
death in diabetic and non-diabetic populations [6].
The HbA1c is generated as a result of non-enzymatic
protein glycation which occurs during hyperglycae-
mia. There was a significant decrease in HbA1c level
after the 3-month treatment in both groups in our
study. This desirable result suggests a decrease in pro-
tein glycation and, probably, a lessening of ED. After
trandolapril therapy the positive linear associations be-
tween HbA1c and insulin and HOMA-IR were no
longer observed. This is a positive influence of ACE
inhibitor on CM and is due to the probable increase of
tissue insulin sensitivity as evidenced by the fact that
the fasting glucose decreased to the level observed in
the controls. There was no such linear association in
the group treated with losartan.
It seems that AT1 antagonists may affect glycation
differently from ACE inhibitor, although the differ-
ence between the groups treated cannot be overlooked.
Group B had higher WHR than Group A in compari-
son with the controls, which suggests the possibility of
more severe metabolic disturbances due to increased
abdominal adipose tissue deposit. Compared to the
controls Group B was characterised by higher glucose,
HbA1c, homocysteine and lower vWF:Ag than group
A before treatment. The lowering of HbA1c in the
group treated with trandolapril in the face of no
change in HOMA-IR and the vanishing of positive
linear correlations between HbA1c and insulin and
HOMA-IR after treatment could be interpreted as
a pathogenic association between insulin resistance
and protein glycation. It seems that in this case ACE
inhibitors affect the glycation process without any in-
fluence on insulin sensitivity. It is known that the pos-
itive metabolic effect of ACE inhibitors results from
decreased bradykinin degradation. Bradykinin may af-
fect glucose metabolism through the increase in its
peripheral tissue uptake, a decrease in endogenous
glucose production and an increase in glycolysis [7].
The HOPE and CAPPP studies showed the desirable
effects of ACE inhibitor on insulin sensitivity, although
this was not confirmed in the STOP-2 trial [8]. Data
concerning trandolapril and carbohydrate metabolism
disturbances in non-diabetic patients is ambiguous.
The TRIS study showed a decrease in insulin resistance
in obese hypertensives treated with trandolapril [9].
This was not confirmed in the study on an EH non-
diabetic group which did not reveal any impact of
trandolapril on glucose or on insulin resistance [10].
A direct comparison of trandolapril and losartan
showed a superiority in the ACE inhibitor influence
on insulin resistance in postmenopausal hypertensive
women [11]. A significant improvement in insulin
sensitivity was demonstrated for losartan in other studies
with severe hypertensives, probably due to the decrease
in sympathetic system activity [12]. Recent data [13] has
shown that both ACE inhibitors and AT1 antagonists
lower in vitro formation of AGE (advanced glycation
end products), which may partially explain the HbA1c
decrease in our study.
We consider vWF:Ag, one of the endothelium-
-derived adhesive glycoproteins, to be an ED and
damage marker [14]. vWF:Ag alone is recognised and
used to determine endothelial status in EH [15], al-
though the addition of selectins, VCAM-1 or ICAM-1
might be useful because vWF:Ag is also an acute
phase reactant. vWF:Ag is constitutively secreted to
plasma as well as stored and released by means of
exocytosis from the secretory granules of endotheli-
um known as the Weibel-Palade bodies. It plays
a role in primary haemostasis but its increased level
is associated with clotting, a prothrombotic state and
a higher cardiovascular risk, as has been shown in
ARIC, ECAT and other studies [16, 17]. In addition
to the lowering of HbA1c and MAP in both groups in
our study, there was a difference in vWF:Ag change
after treatment. The vWF:Ag level showed, as de-
sired, a decrease in the group treated with losartan
but an increase in the trandolapril group. This phe-
nomenon is in disagreement with data showing
a positive association between vWF:Ag and insulin
resistance in non-diabetic EH [18]. There is also data
concerning the lack of ACE inhibitor influence on
vWF:Ag in normotensive diabetic patients and
healthy volunteers [19].
No change in vWF:Ag was found in EH after
8 weeks of losartan treatment [14]. Although losartan
has uricosuric properties (due to the inhibition of uric
acid proximal tubule reabsorption), there was no uric
acid level change after losartan therapy. In this case,
therefore, the lowering of vWF:Ag in group A cannot
be explained by uric acid level correction. We suppose
that the different influence of losartan and trandol-
april on vWF:Ag in our study might be the result of
metabolic differences found at the start between the
groups treated. This means that even clinically similar
hypertensive patients may respond to therapy in dif-
ferent ways. Beyond any doubt the weakness of this
study was that it was not randomised and that it lacked
cross-over design. Instead the sole purpose was to
compare the effect of two drugs in patients who on
a clinical basis were similar. The similarity between
them (in respect of age, blood pressure and BMI)
blurred the metabolic disturbance differences. Patients
randomly allocated to losartan therapy revealed differ-
ences in HbA1c, homocysteine and vWF:Ag when
compared to the controls.
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Conclusions
AT1-antagonist losartan and ACE-inhibitor tran-
dolapril in monotherapy corrected impaired glucose
metabolism (assessed by a decrease in HbA1c level)
besides lowering blood pressure in overweight mild
to moderate EH patients. AT1-antagonist losartan
had a beneficial effect on ED (as assessed by a de-
crease in vWF:Ag level), which may emphasise the
influence of CM and oxidative stress on endotheli-
um in EH. A group of mild to moderate EH pa-
tients, while clinically similar, may respond in differ-
ent ways to the treatment process, which may be
a result of the severity of the metabolic disturbances
found in this group.
Abstract
Background Carbohydrate metabolism disturbances
(CM) and endothelial dysfunction (ED) often coex-
ist with essential arterial hypertension (EH).
Material and Methods In order to investigate the
effect of AT1-antagonist losartan in a daily dose of
50 mg and ACE-inhibitor trandolapril in a daily dose
of 2 mg on CM and ED in untreated EH the follow-
ing were evaluated in mild to moderate EH patients
during fasting: glucose, insulin, total homocysteine,
HbA1c, uric acid, von Willebrand Factor (vWF:Ag),
HOMA-IR, BMI and WHR and the results com-
pared to those for matched controls. The examina-
tion was repeated after 3 months in both the groups
treated.
Results A decrease in HbA1c in both groups treated
suggests CM correction besides the lowering of blood
pressure. There was a decrease in the vWF:Ag level
in the losartan group and an increase in the vWF:Ag
level in the group treated with trandolapril. This dif-
ference in vWF:Ag (known as an ED marker) may
be explained by the distinct way in which the drugs
under examination influenced the renin-angiotensin-
-aldosterone system and by the possible role of ki-
nins, the activity of which is elevated during ACE-
-inhibitor treatment. The trandolapril group had
a higher WHR than the losartan group when com-
pared to controls, which implies the possibility of
more severe CM due to increased abdominal adipose
tissue deposit. It was also characterised by higher
fasting glucose, HbA1c, total homocysteine than the
losartan group when compared to controls before
treatment.
Conclusions Our data may suggest that mild to mode-
rate EH patients, even when clinically similar, may
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